Martine A. Rothblatt, serving as both Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), executed a significant sale of company equity on July 9, 2026. The transaction involved the disposition of 9,500 common shares, generating a total value of $5,235,756. The shares were sold at prices fluctuating between $547.61 and $555.77 per unit. This activity follows the exercise of 9,500 stock options, which Ms. Rothblatt had acquired at a cost of $135.42 per share, amounting to a total acquisition value of $1,286,489.
The sales were processed under a pre-arranged 10b5-1 trading plan, a mechanism designed to facilitate insider transactions in compliance with securities regulations. Ms. Rothblatt initially adopted this plan on November 7, 2025. The plan is structured to remain active until the earlier of two specific milestones: the exercise of 1,734,410 stock options, all of which are set to expire on March 15, 2027, or the final day of the calendar year 2026.
Following the completion of these transactions, Ms. Rothblatt's direct ownership in United Therapeutics stands at 40,513 shares. Her broader indirect holdings include 166 shares held by her spouse and a substantial portfolio of 628,049 shares managed through various family trusts. Additionally, a family trust holds 349,192 shares underlying stock options. These options carry an exercise price of $135.42 and are exercisable from March 15, 2023, through March 15, 2027.
At the time of reporting, UTHR stock was trading at $552.48, marking an 84% gain over the previous twelve months. Despite this strong performance, analysis suggests the stock may be overvalued relative to its fair value, placing it among companies categorized as overvalued in market assessments. The stock experienced a minor decline of $0.48, or 0.09%, in after-hours trading, closing at $552.00.
Beyond the executive transaction, United Therapeutics has announced several operational developments. The U.S. Food and Drug Administration has granted premarket approval for the LungFX device. This technology is designed for centralized ex vivo lung perfusion, allowing for the assessment of donor lungs outside the human body prior to transplantation. The device aims to enhance the evaluation process for deceased-donor lungs.
Furthermore, the company reported that its TETON-1 phase 3 study of nebulized Tyvaso in the treatment of idiopathic pulmonary fibrosis successfully met its primary endpoint. The results, published in the New England Journal of Medicine, indicated that Tyvaso preserved lung function and reduced the risk of clinical worsening events.
In a separate strategic move, United Therapeutics announced a collaboration with Varda Space Industries. The partnership aims to explore microgravity-based pharmaceutical processing for rare pulmonary diseases. The initiative seeks to utilize microgravity conditions to enhance the structure and crystallization properties of therapeutic compounds.
Market analysts have also weighed in on the company's prospects. TD Cowen reiterated a Buy rating on United Therapeutics stock, maintaining a price target of $675.00. This rating reflects confidence in the company's ongoing advancements in medical technology and its collaborations within the pharmaceutical sector.